← All organizations
Highest phase reached
Phase 1
First clinical trial
Jun 30, 2018Last known activity
Apr 30, 2024
Timeline
2010s
- Jan 1, 2018
Allife Medical Science and Technology Co., Ltd.— Founded
Drugs by trial phase (13 distinct, 13 trials)
Phase 1 (13 own, 0 via acquisition)
- autologous natural killer cells
- pembrolizumab
- autologous dendritic cells
- mesothelin car t cells
- cd19 car-t cells
- autologous cytokine induced killer cells
- endothelial progenitor cells
- cd22 car-t cells
- autologous mesenchymal stem cell-derived neural progenitors
- anti-psma car nk cells
- autologous cd19/cd22 chimeric antigen receptor t-cells
- ciltacabtagene autoleucel
- Neural Stem Cell-Derived Neurons
Indications
Recent trials (13)
- NCT06359912Lead sponsorPhase 1Apr 30, 2024
- NCT05993884Lead sponsorPhase 1Aug 15, 2023
- NCT03725865Lead sponsorEarly Phase 1Mar 31, 2019
- NCT03824951Lead sponsorEarly Phase 1Feb 1, 2019
- NCT03815084Lead sponsorEarly Phase 1Feb 1, 2019
- NCT03815071Lead sponsorEarly Phase 1Feb 1, 2019
- NCT03815630Lead sponsorEarly Phase 1Feb 1, 2019
- NCT03824964Lead sponsorEarly Phase 1Feb 1, 2019
- NCT03692663Lead sponsorEarly Phase 1Dec 31, 2018
- NCT03692637Lead sponsorEarly Phase 1Nov 30, 2018
- NCT03692767Lead sponsorEarly Phase 1Nov 30, 2018
- NCT03690310Lead sponsorEarly Phase 1Nov 30, 2018
- NCT03559764Lead sponsorEarly Phase 1Jun 30, 2018
Details
- Founded
- Beijing, CN Jan 1, 2018
- Last known activity
- Apr 30, 2024